Heart Failure with Preserved Ejection Fraction Induces Beiging in Adipose Tissue

Circulation: Heart Failure

Volumn 9, Issue 1, 2016, Pages

  Valero Munõz, Mariá ^a   Li, Shanpeng ^a   Wilson, Richard M ^a   Hulsmans, Maarten ^b   Aprahamian, Tamar ^a   Fuster, José J ^a   Nahrendorf, Matthias ^b   Scherer, Philipp E ^c   Sam, Flora ^a  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Brown adipose tissue; diastolic heart failure; natriuretic peptides; white adipose tissue

Indexed keywords

ALDOSTERONE; CELL DEATH INDUCING DFFA LIKE EFFECTOR; EPITHELIAL V LIKE ANTIGEN; FATTY ACID BINDING PROTEIN 4; GLUCOSE; HORMONE SENSITIVE LIPASE; LIPOPROTEIN LIPASE; MITOGEN ACTIVATED PROTEIN KINASE P38; NATRIURETIC PEPTIDE RECEPTOR TYPE A; PROTEIN; SODIUM CHLORIDE; UNCLASSIFIED DRUG; UNCOUPLING PROTEIN 1; AUTACOID; BIOLOGICAL MARKER;

ADIPOCYTE; ADIPOSE TISSUE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA CONSTRICTION; ARTICLE; BODY TEMPERATURE; BODY WEIGHT; CELL SIZE; COLD; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DIASTOLIC DYSFUNCTION; ECHOCARDIOGRAPHY; ENVIRONMENTAL EXPOSURE; ENZYME ACTIVATION; EPIDIDYMIS; GASTROCNEMIUS MUSCLE; GLUCOSE BLOOD LEVEL; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE HYPERTROPHY; HEART RATE; HYPERTENSION; LIVER WEIGHT; LUNG WEIGHT; MACROPHAGE; MONOCYTE; MOUSE; NEUTROPHILIA; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SPLEEN WEIGHT; SYSTOLIC BLOOD PRESSURE; UNINEPHRECTOMY; ANIMAL; BROWN ADIPOCYTE; BROWN ADIPOSE TISSUE; C57BL MOUSE; CARDIAC MUSCLE CELL; CHEMICALLY INDUCED; DISEASE MODEL; FIBROSIS; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; METABOLISM; NEPHRECTOMY; OXIDATIVE STRESS; PATHOLOGY; PATHOPHYSIOLOGY; THERMOREGULATION; TIME FACTOR; WHITE ADIPOCYTE; WHITE ADIPOSE TISSUE;

ADIPOCYTES, BROWN; ADIPOCYTES, WHITE; ADIPOSE TISSUE, BROWN; ADIPOSE TISSUE, WHITE; ALDOSTERONE; ANIMALS; BIOMARKERS; BODY TEMPERATURE REGULATION; DISEASE MODELS, ANIMAL; FIBROSIS; HEART FAILURE; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INFLAMMATION MEDIATORS; MICE, INBRED C57BL; MYOCYTES, CARDIAC; NEPHRECTOMY; OXIDATIVE STRESS; PHENOTYPE; SIGNAL TRANSDUCTION; STROKE VOLUME; TIME FACTORS; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 84955325359     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.115.002724     Document Type: Article

References (48)

1. Borlaug BA. The pathophysiology of heart failure with preserved ejection fraction. Nat Rev Cardiol. 2014;11:507-515. doi: 10.1038/nrcardio.2014.83.
2. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL. 2013 ACCF/AHA guideline for the management of heart failure: executive summary: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:1810-1852. doi: 10.1161/CIR.0b013e31829e8807.
3. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781. doi: 10.1016/S0140-6736(03)14285-7.
4. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. doi: 10.1093/eurheartj/ehl250.
5. van Veldhuisen DJ, Cohen-Solal A, Bm M, Anker SD, Babalis D, Roughton M, Coats AJ, Poole-Wilson PA, Flather MD; SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: Data From SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150-2158. doi: 10.1016/j.jacc.2009.02.046.
6. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O'Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM; TOPCAT Investigators. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383-1392. doi: 10.1056/NEJMoa1313731.
7. Owan TE, Hodge DO, Herges RM, Jacobsen SJ, Roger VL, Redfield MM. Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med. 2006;355:251-259. doi: 10.1056/NEJMoa052256.
8. Haass M, Kitzman DW, Anand IS, Miller A, Zile MR, Massie BM, Carson PE. Body mass index and adverse cardiovascular outcomes in heart failure patients with preserved ejection fraction: results from the Irbesartan in Heart Failure with Preserved Ejection Fraction (I-PRESERVE) trial. Circ Heart Fail. 2011;4:324-331. doi: 10.1161/CIRCHEARTFAILURE.110.959890.
9. Mohammed SF, Borlaug BA, Roger VL, Mirzoyev SA, Rodeheffer RJ, Chirinos JA, Redfield MM. Comorbidity and ventricular and vascular structure and function in heart failure with preserved ejection fraction: a community-based study. Circ Heart Fail. 2012;5:710-719. doi: 10.1161/CIRCHEARTFAILURE.112.968594.
10. Mentz RJ, Kelly JP, von Lueder TG, Voors AA, Lam CS, Cowie MR, Kjeldsen K, Jankowska EA, Atar D, Butler J, Fiuzat M, Zannad F, Pitt B, O'Connor CM. Noncardiac comorbidities in heart failure with reduced versus preserved ejection fraction. J Am Coll Cardiol. 2014;64:2281-2293. doi: 10.1016/j.jacc.2014.08.036.
11. Kenchaiah S, Evans JC, Levy D, Wilson PW, Benjamin EJ, Larson MG, Kannel WB, Vasan RS. Obesity and the risk of heart failure. N Engl J Med. 2002;347:305-313. doi: 10.1056/NEJMoa020245.
12. Lee DS, Gona P, Vasan RS, Larson MG, Benjamin EJ, Wang TJ, Tu JV, Levy D. Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the framingham heart study of the national heart, lung, and blood institute. Circulation. 2009;119:3070-3077. doi: 10.1161/CIRCULATIONAHA.108.815944.
13. Haykowsky MJ, Kouba EJ, Brubaker PH, Nicklas BJ, Eggebeen J, Kitzman DW. Skeletal muscle composition and its relation to exercise intolerance in older patients with heart failure and preserved ejection fraction. Am J Cardiol. 2014;113:1211-1216. doi: 10.1016/j.amjcard.2013.12.031.
14. Kitzman DW, Upadhya B, Vasu S. What the dead can teach the living: systemic nature of heart failure with preserved ejection fraction. Circulation. 2015;131:522-524. doi: 10.1161/CIRCULATIONAHA.114.014420.
15. Sam F, Duhaney TA, Sato K, Wilson RM, Ohashi K, Sono-Romanelli S, Higuchi A, De Silva DS, Qin F, Walsh K, Ouchi N. Adiponectin deficiency, diastolic dysfunction, and diastolic heart failure. Endocrinology. 2010;151:322-331. doi: 10.1210/en.2009-0806.
16. Tanaka K, Wilson RM, Essick EE, Duffen JL, Scherer PE, Ouchi N, Sam F. Effects of adiponectin on calcium-handling proteins in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:976-985. doi: 10.1161/CIRCHEARTFAILURE.114.001279.
17. Shimano M, Ouchi N, Walsh K. Cardiokines: recent progress in elucidating the cardiac secretome. Circulation. 2012;126:e327-e332. doi: 10.1161/CIRCULATIONAHA.112.150656.
18. Loncar G, Fster S, von Haehling S, Popovic V. Metabolism and the heart: an overview of muscle, fat, and bone metabolism in heart failure. Int J Cardiol. 2013;162:77-85. doi: 10.1016/j.ijcard.2011.09.079.
19. Nakamura M, Sadoshima J. Heart over mind: metabolic control of white adipose tissue and liver. EMBO Mol Med. 2014;6:1521-1524. doi: 10.15252/emmm.201404749.
20. Baskin KK, Grueter CE, Kusminski CM, Holland WL, Bookout AL, Satapati S, Kong YM, Burgess SC, Malloy CR, Scherer PE, Newgard CB, Bassel-Duby R, Olson EN. MED13-dependent signaling from the heart confers leanness by enhancing metabolism in adipose tissue and liver. EMBO Mol Med. 2014;6:1610-1621. doi: 10.15252/emmm.201404218.
21. Sengen C, Berlan M, De Glisezinski I, Lafontan M, Galitzky J. Natriuretic peptides: a new lipolytic pathway in human adipocytes. FASEB J. 2000;14:1345-1351.
22. Moro C, Crampes F, Sengenes C, De Glisezinski I, Galitzky J, Thalamas C, Lafontan M, Berlan M. Atrial natriuretic peptide contributes to physiological control of lipid mobilization in humans. FASEB J. 2004;18:908-910. doi: 10.1096/fj.03-1086fje.
23. Bordicchia M, Liu D, Amri EZ, Ailhaud G, DessFulgheri P, Zhang C, Takahashi N, Sarzani R, Collins S. Cardiac natriuretic peptides act via p38 MAPK to induce the brown fat thermogenic program in mouse and human adipocytes. J Clin Invest. 2012;122:1022-1036. doi: 10.1172/JCI59701.
24. Wilson RM, De Silva DS, Sato K, Izumiya Y, Sam F. Effects of fixeddose isosorbide dinitrate/hydralazine on diastolic function and exercise capacity in hypertension-induced diastolic heart failure. Hypertension. 2009;54:583-590. doi: 10.1161/HYPERTENSIONAHA.109.134932.
25. Orr JS, Kennedy AJ, Hasty AH. Isolation of adipose tissue immune cells. J Vis Exp 2013; 75:e50707.
26. Heidt T, Courties G, Dutta P, Sager HB, Sebas M, Iwamoto Y, Sun Y, Da Silva N, Panizzi P, van der Laan AM, van der Lahn AM, Swirski FK, Weissleder R, Nahrendorf M. Differential contribution of monocytes to heart macrophages in steady-state and after myocardial infarction. Circ Res. 2014;115:284-295. doi: 10.1161/CIRCRESAHA.115.303567.
27. Petruzzelli M, Schweiger M, Schreiber R, Campos-Olivas R, Tsoli M, Allen J, Swarbrick M, Rose-John S, Rincon M, Robertson G, Zechner R, Wagner EF. A switch from white to brown fat increases energy expenditure in cancer-associated cachexia. Cell Metab. 2014;20:433-447. doi: 10.1016/j.cmet.2014.06.011.
28. Nguyen KD, Qiu Y, Cui X, Goh YP, Mwangi J, David T, Mukundan L, Brombacher F, Locksley RM, Chawla A. Alternatively activated macrophages produce catecholamines to sustain adaptive thermogenesis. Nature. 2011;480:104-108. doi: 10.1038/nature10653.
29. Zhang Y, Li R, Meng Y, Li S, Donelan W, Zhao Y, Qi L, Zhang M, Wang X, Cui T, Yang LJ, Tang D. Irisin stimulates browning of white adipocytes through mitogen-activated protein kinase p38 MAP kinase and ERK MAP kinase signaling. Diabetes. 2014;63:514-525. doi: 10.2337/db13-1106.
30. Nedergaard J, Cannon B. The browning of white adipose tissue: some burning issues. Cell Metab. 2014;20:396-407. doi: 10.1016/j. cmet.2014.07.005.
31. Harms M, Seale P. Brown and beige fat: development, function and therapeutic potential. Nat Med. 2013;19:1252-1263. doi: 10.1038/nm.3361.
32. Lafontan M. Advances in adipose tissue metabolism. Int J Obes (Lond). 2008;32(suppl 7):S39-S51. doi: 10.1038/ijo.2008.237.
33. Cannon B, Nedergaard J. Nonshivering thermogenesis and its adequate measurement in metabolic studies. J Exp Biol. 2011;214(pt 2):242-253. doi: 10.1242/jeb.050989.
34. Virtanen KA, Lidell ME, Orava J, Heglind M, Westergren R, Niemi T, Taittonen M, Laine J, Savisto NJ, Enerbk S, Nuutila P. Functional brown adipose tissue in healthy adults. N Engl J Med. 2009;360:1518-1525. doi: 10.1056/NEJMoa0808949.
35. van Marken Lichtenbelt WD, Vanhommerig JW, Smulders NM, Drossaerts JM, Kemerink GJ, Bouvy ND, Schrauwen P, Teule GJ. Cold-activated brown adipose tissue in healthy men. N Engl J Med. 2009;360:1500-1508. doi: 10.1056/NEJMoa0808718.
36. Cypess AM, Lehman S, Williams G, Tal I, Rodman D, Goldfine AB, Kuo FC, Palmer EL, Tseng YH, Doria A, Kolodny GM, Kahn CR. Identification and importance of brown adipose tissue in adult humans. N Engl J Med. 2009;360:1509-1517. doi: 10.1056/NEJMoa0810780.
37. Sidossis L, Kajimura S. Brown and beige fat in humans: thermogenic adipocytes that control energy and glucose homeostasis. J Clin Invest. 2015;125:478-486. doi: 10.1172/JCI78362.
38. Feldmann HM, Golozoubova V, Cannon B, Nedergaard J. UCP1 ablation induces obesity and abolishes diet-induced thermogenesis in mice exempt from thermal stress by living at thermoneutrality. Cell Metab. 2009;9:203-209. doi: 10.1016/j.cmet.2008.12.014.
39. Glezeva N, Voon V, Watson C, Horgan S, McDonald K, Ledwidge M, Baugh J. Exaggerated inflammation and monocytosis associate with diastolic dysfunction in heart failure with preserved ejection fraction: evidence of M2 macrophage activation in disease pathogenesis. J Card Fail. 2015;21:167-177. doi: 10.1016/j.cardfail.2014.11.004.
40. Buglioni A, Burnett JC Jr. Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. Clin Chim Acta. 2015;443:3-8. doi: 10.1016/j.cca.2014.10.027.
41. Ghigliotti G, Barisione C, Garibaldi S, Fabbi P, Brunelli C, Spallarossa P, Altieri P, Rosa G, Spinella G, Palombo D, Arsenescu R, Arsenescu V. Adipose tissue immune response: novel triggers and consequences for chronic inflammatory conditions. Inflammation. 2014;37:1337-1353. doi: 10.1007/s10753-014-9914-1.
42. Nijhuis J, Rensen SS, Slaats Y, van Dielen FM, Buurman WA, Greve JW. Neutrophil activation in morbid obesity, chronic activation of acute inflammation. Obesity (Silver Spring). 2009;17:2014-2018. doi: 10.1038/oby.2009.113.
43. Talukdar S, Oh da Y, Bandyopadhyay G, Li D, Xu J, McNelis J, Lu M, Li P, Yan Q, Zhu Y, Ofrecio J, Lin M, Brenner MB, Olefsky JM. Neutrophils mediate insulin resistance in mice fed a high-fat diet through secreted elastase. Nat Med. 2012;18:1407-1412. doi: 10.1038/nm.2885.
44. Wang Q, Xie Z, Zhang W, Zhou J, Wu Y, Zhang M, Zhu H, Zou MH. Myeloperoxidase deletion prevents high-fat diet-induced obesity and insulin resistance. Diabetes. 2014;63:4172-4185. doi: 10.2337/db14-0026.
45. Sun K, Wernstedt Asterholm I, Kusminski CM, Bueno AC, Wang ZV, Pollard JW, Brekken RA, Scherer PE. Dichotomous effects of VEGF-A on adipose tissue dysfunction. Proc Natl Acad Sci USA. 2012;109:5874-5879. doi: 10.1073/pnas.1200447109.
46. Sun K, Kusminski CM, Luby-Phelps K, Spurgin SB, An YA, Wang QA, Holland WL, Scherer PE. Brown adipose tissue derived VEGF-A modulates cold tolerance and energy expenditure. Mol Metab. 2014;3:474-483. doi: 10.1016/j.molmet.2014.03.010.
47. Whittle AJ, Vidal-Puig A. NPs-heart hormones that regulate brown fat J Clin Invest. 2012;122:804-807. doi: 10.1172/JCI62595.
48. Lee SD, Tontonoz P. Eosinophils in fat: pink is the new brown. Cell. 2014;157:1249-1250. doi: 10.1016/j.cell.2014.05.025.